In the meantime, AG-270, another MAT2A inhibitor with high affinity, has been developed that is already undergoing a phase I clinical trial in patients suffering from lymphoma or solid tumors (NCT03435250, clinical trials.gov), supporting the rationale to target MAT2A in leukemia. This evidence concerns the gene MAT2A and leukemia.